Drugs Made In America Acquisition Corp. Files S-1/A Amendment

TL;DR

SPAC filing update for Drugs Made In America Acquisition Corp. - moving forward.

AI Summary

Drugs Made In America Acquisition Corp. filed an S-1/A amendment on September 27, 2024, for its registration statement (No. 333-281170). The company, incorporated in the Cayman Islands, is a blank check company focused on the 'Drugs Made In America' sector. Its principal executive offices are located at 2 Pelican Dr., Fort Lauderdale, FL 33301.

Why It Matters

This S-1/A filing indicates that Drugs Made In America Acquisition Corp. is moving forward with its plans as a special purpose acquisition company (SPAC), potentially leading to a future merger or acquisition in the pharmaceutical or related industries.

Risk Assessment

Risk Level: medium — As a blank check company, its success is contingent on identifying and completing a suitable acquisition, which carries inherent risks.

Key Numbers

• 333-281170 — SEC File Number (Identifies this specific registration)

Key Players & Entities

• Drugs Made In America Acquisition Corp. (company) — Registrant
• 333-281170 (dollar_amount) — SEC File Number
• September 27, 2024 (date) — Filing Date
• Lynn Stockwell (person) — Executive Chair
• 2 Pelican Dr., Fort Lauderdale, FL 33301 (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $500,000,000 — ER 26 , 2024 PRELIMINARY PROSPECTUS $500,000,000 Drugs Made In America Acquisition Cor
• $10.00 — ies. Each unit has an offering price of $10.00 and consists of one ordinary share and
• $0.10 — onsor depositing into the trust account $0.10 per public share outstanding in
• $100,000 — awn to pay our taxes, if any, and up to $100,000 of interest to pay dissolution expenses
• $4,500,000 — ) at a price of $10.00 per unit ($4,500,000 in the aggregate, or $4,875,000 in the
• $4,875,000 — r unit ($4,500,000 in the aggregate, or $4,875,000 in the aggregate if the underwriters&#x
• $35,000 — dinary shares (which were purchased for $35,000 and which we refer to as “founde
• $0.05 — #x00a0;     $0.05 per unit sold in the base offering, or
• $2,500,000 — per unit sold in the base offering, or $2,500,000 (or up to $2,875,000 if the overallotme
• $2,875,000 — base offering, or $2,500,000 (or up to $2,875,000 if the overallotment option is exercise
• $0.25 — the closing of this offering. Includes $0.25 per unit, or $12,500,000 (or up to $14,
• $12,500,000 — s offering. Includes $0.25 per unit, or $12,500,000 (or up to $14,375,000 if the underwrite
• $14,375,000 — 0.25 per unit, or $12,500,000 (or up to $14,375,000 if the underwriters’ over -allot
• $500.0 — ate units described in this prospectus, $500.0 million, or $575.0 millio
• $575.0 — s prospectus, $500.0 million, or $575.0 million if the underwriters&#x20

Filing Documents

• ea0209546-04.htm (S-1/A) — 4268KB
• ea020954604ex1-1_drugs.htm (EX-1.1) — 250KB
• ea020954604ex3-3_drugs.htm (EX-3.3) — 261KB
• ea020954604ex4-1_drugs.htm (EX-4.1) — 19KB
• ea020954604ex4-2_drugs.htm (EX-4.2) — 17KB
• ea020954604ex4-4_drugs.htm (EX-4.4) — 68KB
• ea020954604ex5-1_drugs.htm (EX-5.1) — 38KB
• ea020954604ex5-2_drugs.htm (EX-5.2) — 11KB
• ea020954604ex10-3_drugs.htm (EX-10.3) — 55KB
• ea020954604ex10-4_drugs.htm (EX-10.4) — 101KB
• ea020954604ex10-5_drugs.htm (EX-10.5) — 96KB
• ea020954604ex10-6_drugs.htm (EX-10.6) — 23KB
• ea020954604ex10-7_drugs.htm (EX-10.7) — 93KB
• ea020954604ex10-8_drugs.htm (EX-10.8) — 14KB
• ea020954604ex14_drugs.htm (EX-14) — 48KB
• ea020954604ex23-1_drugs.htm (EX-23.1) — 4KB
• ea020954604ex99-4_drugs.htm (EX-99.4) — 37KB
• ea020954604ex99-5_drugs.htm (EX-99.5) — 31KB
• ex5-2_001.jpg (GRAPHIC) — 4KB
• ex5-1_001.jpg (GRAPHIC) — 11KB
• ex5-1_002.jpg (GRAPHIC) — 12KB
• 0001213900-24-082386.txt ( ) — 5473KB

Risk factors

Risk factors   34 Cautionary note regarding forward-looking statements   73

Use of proceeds

Use of proceeds   75 Dividend policy   79

Dilution

Dilution   80 Capitalization   83 Management’s discussion and analysis of financial condition and resul ts of operations   84 Proposed business   89 Management   113 Principal shareholders   121 Certain relationships and related party transactions   124

Description of securities

Description of securities   127 MATERIAL United states federal income tax considerations   142

Underwriting

Underwriting   151 Legal matters   160 Experts   160 Where you can find additional information   160 Index to Financial Statements   F-1 This prospectus contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. i Table of Contents Summary This summary only highlights the more detailed information appearing elsewhere in this prospectus. As this is a summary, it does not contain all of the information that you should consider in making an investment decision. You should read this entire prospectus carefully, including the information under “Risk Factors” and our financial statements and the related notes included elsewhere in this prospectus, before investing. General Drugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses, which we refer to throughout this prospectus as our “initial business combination.” To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive disc

View Full Filing

View this S-1/A filing on SEC EDGAR